Bioeq AG
Thiemo Schreiber, PhD, serves as the Vice President of Commercial & Operations and leads Business Development at Bioeq AG since July 2017. Previously, Thiemo held business development roles in biologics at Polpharma and was the Head of PMO at Swiss Pharma International AG. With experience as a Project Portfolio Manager at Alfred E. Tiefenbacher and a consultant at The Boston Consulting Group, Thiemo has a strong background in strategic management and in-house consulting. Educationally, Thiemo earned a Dr. rer. nat. in Proteomics and cancer research from the Max-Planck-Institute for Biochemistry and a Dipl. Biochem. in Biochemistry and Molecular Biology from the University of Hamburg.
This person is not in any teams
This person is not in any offices
Bioeq AG
Bioeq AG is a Swiss biopharmaceutical joint venture backed by the leading biosimilar developers Polpharma Biologics Group and Formycon AG and is based in Zug. We license, develop and commercialise a biosimilar, which is a successor product of Lucentis® (ranibizumab), a successful branded biopharmaceutical. We are a young and dynamic company, supported by an international network of experts. Bioeq AG out-licenses its products to established international pharmaceutical companies who ensure local distribution in each territory.